Exenatide vs Liraglutide
Research Verdict
Liraglutide is the stronger research reference for the stated comparison criteria. Liraglutide: LEADER trial (n=9,340, HR 0.87 for MACE, p=0.01) demonstrated cardiovascular benefit.
Quick Answers
Which is better, Exenatide or Liraglutide?
Liraglutide is the stronger research reference for the stated comparison criteria. Liraglutide: LEADER trial (n=9,340, HR 0.87 for MACE, p=0.01) demonstrated cardiovascular benefit.
What is the key difference between Exenatide and Liraglutide?
Exenatide (Byetta: twice daily; Bydureon: once weekly) was the first-in-class GLP-1RA; liraglutide (Victoza: once daily) demonstrated the first positive CVOT in the class, establishing the cardiovascular benefit paradigm.
Evidence Comparison
Liraglutide: LEADER trial (n=9,340, HR 0.87 for MACE, p=0.01) demonstrated cardiovascular benefit. Exenatide: EXSCEL trial (n=14,752, HR 0.91, p=0.06) was neutral - no statistically significant CV benefit. Both FDA approved, but liraglutide has the stronger outcomes evidence.
Evidence Context Favoring Exenatide
Research requiring once-weekly extended-release GLP-1RA dosing (Bydureon formulation) or first-in-class historical comparisons.
Evidence Context Favoring Liraglutide
Research requiring demonstrated cardiovascular benefit from a GLP-1RA, or where CVOT-positive status is an inclusion criterion.
Side-by-Side Snapshot
| Evidence grade | Exenatide: Level A Liraglutide: Level A |
|---|---|
| Research status | Exenatide: FDA Approved Liraglutide: FDA Approved |
| Primary category | Exenatide: Weight Loss & Metabolic Liraglutide: Weight Loss & Metabolic |
| Cited studies | Exenatide: 3 Liraglutide: 2 |